Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

Cited In for PubMed (Select 17687130)

1.

Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years.

Hammers CM, Chen J, Lin C, Kacir S, Siegel DL, Payne AS, Stanley JR.

J Invest Dermatol. 2015 Mar;135(3):742-9. doi: 10.1038/jid.2014.291. Epub 2014 Jul 14.

PMID:
25142730
2.

A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone.

Hall RP 3rd, Fairley J, Woodley D, Werth VP, Hannah D, Streilein RD, McKillip J, Okawa J, Rose M, Keyes-Elstein LL, Pinckney A, Overington A, Wedgwood J, Ding L, Welch B.

Br J Dermatol. 2015 Mar;172(3):760-8. doi: 10.1111/bjd.13350. Epub 2015 Feb 5.

PMID:
25123295
3.

Management of pemphigus.

Daniel BS, Murrell DF.

F1000Prime Rep. 2014 May 6;6:32. doi: 10.12703/P6-32. eCollection 2014. Review.

4.

Severe multi-resistant pemphigus vulgaris: prolonged remission with a single cycle of rituximab.

Corral IS, Freitas TH, Aquino RT, Koller DA, Magliari ME, Muller H.

An Bras Dermatol. 2013 Jul-Aug;88(4):639-42. doi: 10.1590/abd1806-4841.20131990.

5.

Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita.

Ludwig RJ.

ISRN Dermatol. 2013 Jul 15;2013:812029. doi: 10.1155/2013/812029. eCollection 2013.

6.
7.

Rituximab in the treatment of pemphigus vulgaris.

Zakka LR, Shetty SS, Ahmed AR.

Dermatol Ther (Heidelb). 2012 Dec;2(1):17. doi: 10.1007/s13555-012-0017-3. Epub 2012 Nov 15.

8.

Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients.

Lunardon L, Tsai KJ, Propert KJ, Fett N, Stanley JR, Werth VP, Tsai DE, Payne AS.

Arch Dermatol. 2012 Sep;148(9):1031-6. doi: 10.1001/archdermatol.2012.1522.

9.

Rituximab for autoimmune blistering diseases: recent studies, new insights.

Lunardon L, Payne AS.

G Ital Dermatol Venereol. 2012 Jun;147(3):269-76.

10.

Inhibitory human antichimeric antibodies to rituximab in a patient with pemphigus.

Lunardon L, Payne AS.

J Allergy Clin Immunol. 2012 Sep;130(3):800-3. doi: 10.1016/j.jaci.2012.03.022. Epub 2012 Apr 26. No abstract available.

11.

Rituximab in severe skin diseases: target, disease, and dose.

Bennett DD, Ohanian M, Cable CT.

Clin Pharmacol. 2010;2:135-41. doi: 10.2147/CPAA.S10929. Epub 2010 Jul 7.

12.

Desmoglein as a target in skin disease and beyond.

Amagai M, Stanley JR.

J Invest Dermatol. 2012 Mar;132(3 Pt 2):776-84. doi: 10.1038/jid.2011.390. Epub 2011 Dec 22. Review.

13.

Rituximab therapy of recalcitrant bullous dermatoses.

Wollina U, Koch A, Hansel G.

J Dermatol Case Rep. 2008 Mar 29;2(1):4-7. doi: 10.3315/jdcr.2008.1007.

14.

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).

Tony HP, Burmester G, Schulze-Koops H, Grunke M, Henes J, Kötter I, Haas J, Unger L, Lovric S, Haubitz M, Fischer-Betz R, Chehab G, Rubbert-Roth A, Specker C, Weinerth J, Holle J, Müller-Ladner U, König R, Fiehn C, Burgwinkel P, Budde K, Sörensen H, Meurer M, Aringer M, Kieseier B, Erfurt-Berge C, Sticherling M, Veelken R, Ziemann U, Strutz F, von Wussow P, Meier FM, Hunzelmann N, Schmidt E, Bergner R, Schwarting A, Eming R, Hertl M, Stadler R, Schwarz-Eywill M, Wassenberg S, Fleck M, Metzler C, Zettl U, Westphal J, Heitmann S, Herzog AL, Wiendl H, Jakob W, Schmidt E, Freivogel K, Dörner T; GRAID investigators.

Arthritis Res Ther. 2011 May 13;13(3):R75. doi: 10.1186/ar3337.

15.

Challenges in the pursuit of immune tolerance.

Nepom GT, St Clair EW, Turka LA.

Immunol Rev. 2011 May;241(1):49-62. doi: 10.1111/j.1600-065X.2011.01003.x. Review.

16.

B cell depletion in autoimmune diabetes: insights from murine models.

Chamberlain JL, Attridge K, Wang CJ, Ryan GA, Walker LS.

Expert Opin Ther Targets. 2011 Jun;15(6):703-14. doi: 10.1517/14728222.2011.561320. Epub 2011 Mar 3. Review.

17.

B cell-targeted therapy with anti-CD20 monoclonal antibody in a mouse model of Graves' hyperthyroidism.

Ueki I, Abiru N, Kobayashi M, Nakahara M, Ichikawa T, Eguchi K, Nagayama Y.

Clin Exp Immunol. 2011 Mar;163(3):309-17. doi: 10.1111/j.1365-2249.2010.04301.x. Epub 2011 Jan 14.

18.

Homologous regions of autoantibody heavy chain complementarity-determining region 3 (H-CDR3) in patients with pemphigus cause pathogenicity.

Yamagami J, Payne AS, Kacir S, Ishii K, Siegel DL, Stanley JR.

J Clin Invest. 2010 Nov;120(11):4111-7. doi: 10.1172/JCI44425. Epub 2010 Oct 18.

19.

Rituximab: a review of dermatological applications.

Emer JJ, Claire W.

J Clin Aesthet Dermatol. 2009 May;2(5):29-37.

20.

Targeted immunotherapy with rituximab leads to a transient alteration of the IgG autoantibody profile in pemphigus vulgaris.

Müller R, Hunzelmann N, Baur V, Siebenhaar G, Wenzel E, Eming R, Niedermeier A, Musette P, Joly P, Hertl M.

Dermatol Res Pract. 2010;2010:321950. doi: 10.1155/2010/321950. Epub 2010 Jun 30.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk